# Geoffrey W. Smith

> Geoffrey W. Smith is a Series B investor at Digitalis Ventures backing Biotechnology. See 20 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Digitalis Ventures](https://shizune.co/investors/profile/digitalis-ventures)
- Location: New York, United States
- Total investments: 20
- Last investment: Jun 2026
- Lead investor: 25%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/pub/geoffrey-smith/a/565/372

Geoffrey W. Smith is a Series B investor at Digitalis Ventures in New York focused on Biotechnology and Therapeutics. Mr. Geoffrey Smith is the Founder and serves as Managing Partner at Digitalis Ventures. He is also a co-founder and General Partner of Ascent Biomedical Ventures, a New York City-based venture capital firm focused on early-stage life sciences investments. Geoff currently represents Ascent on the Board of Directors for Azevan Pharmaceuticals,BlinkBio, and Orchestra BioMed, and is a Board Observer of Vivasure Medical. Geoff serves as a Trustee of The Jackson Laboratory. He is a Visiting Scholar at Rockefeller University and an adjunct faculty member at the RU Center for Clinical and Translational Science. Geoff also serves as a member of the Scientific Advisory Board for Brigham & Women’s Hospital in Boston. Previously, he was the founding Director of the Mount Sinai Institute of Technology and a Professor in the Department of Population Health Science and Policy at the Icahn School of Medicine at Mount Sinai. Geoff received a B.A. (with honors) from Williams College and a J.D. from the University of Pennsylvania Law School.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 8 | 40% |
| Therapeutics | 4 | 20% |
| Health Care | 3 | 15% |
| Pharmaceutical | 3 | 15% |
| Medical | 2 | 10% |

16 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 6 | 30% |
| Seed | 4 | 20% |
| Series A | 3 | 15% |
| Series C | 2 | 10% |
| Series D | 1 | 5% |

7 stages tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Rejuvenate Bio | Rejuvenate Bio is a biotechnology company that develops novel gene therapies for dogs. The company's therapy provides a solution for the mitral valve disease to stop the progression of heart failure in dogs, thus providing pets with extended overall health and maximal lifespan. It was founded in 2017 and is based in San Diego, CA. | $6M | Venture - Series Unknown | Jun 08, 2026 |  |
| Terray Therapeutics | Terray Therapeutics is a biotechnology company that integrates experimentation and computation to enhance small molecule drug discovery. The platform generates extensive, precise data through a rapid design-make-test-analyze cycle, allowing for efficient exploration of chemical space. By focusing on both wet lab science and AI, the companyaddresses complex therapeutic challenges across various targets. | $120M | Series B | Oct 17, 2024 |  |
| GRO Biosciences | GRO Biosciences is leveraging breakthrough technologies from computational protein design and synthetic biology to develop best-in-class protein therapeutics with enhanced properties. The company has established multiple genomically recoded strains of bacteria that can incorporate non-standard amino acids into proteins to confer increased potency,stability, and targeted delivery. GRO Biosciences is applying its technology platform to develop improved protein therapeutics for diabetes, growth disorders, and autoimmunity. The company, co-founded by Dr. George Church, is located at the Harvard Life Lab, shared laboratory space for high-potential life sciences and biotechnology startups founded by Harvard faculty, alumni, students, and postdoctoral scholars. | $60.3M | Series B | Jul 19, 2024 |  |
| Elemental Machines | Elemental Machines is revolutionizing science-based industries with a smart lab platform that offers powerful, data-driven insights to improve laboratory operations, research, development, and manufacturing outcomes. Continuously monitoring equipment and environmental variables provides new levels of clarity, transparency, consistency, and improvedrepeatability and gathers new data sets for advanced analytics. | $41.9M | Series B | Nov 10, 2022 |  |
| Terray Therapeutics | Terray Therapeutics is a biotechnology company that integrates experimentation and computation to enhance small molecule drug discovery. The platform generates extensive, precise data through a rapid design-make-test-analyze cycle, allowing for efficient exploration of chemical space. By focusing on both wet lab science and AI, the companyaddresses complex therapeutic challenges across various targets. | $60M | Series A | Feb 15, 2022 |  |
| GRO Biosciences | GRO Biosciences is leveraging breakthrough technologies from computational protein design and synthetic biology to develop best-in-class protein therapeutics with enhanced properties. The company has established multiple genomically recoded strains of bacteria that can incorporate non-standard amino acids into proteins to confer increased potency,stability, and targeted delivery. GRO Biosciences is applying its technology platform to develop improved protein therapeutics for diabetes, growth disorders, and autoimmunity. The company, co-founded by Dr. George Church, is located at the Harvard Life Lab, shared laboratory space for high-potential life sciences and biotechnology startups founded by Harvard faculty, alumni, students, and postdoctoral scholars. | $25M | Series A | Nov 01, 2021 |  |
| Terray Therapeutics | Terray Therapeutics is a biotechnology company that integrates experimentation and computation to enhance small molecule drug discovery. The platform generates extensive, precise data through a rapid design-make-test-analyze cycle, allowing for efficient exploration of chemical space. By focusing on both wet lab science and AI, the companyaddresses complex therapeutic challenges across various targets. | $15M | Seed | Jun 30, 2021 |  |
| GRO Biosciences | GRO Biosciences is leveraging breakthrough technologies from computational protein design and synthetic biology to develop best-in-class protein therapeutics with enhanced properties. The company has established multiple genomically recoded strains of bacteria that can incorporate non-standard amino acids into proteins to confer increased potency,stability, and targeted delivery. GRO Biosciences is applying its technology platform to develop improved protein therapeutics for diabetes, growth disorders, and autoimmunity. The company, co-founded by Dr. George Church, is located at the Harvard Life Lab, shared laboratory space for high-potential life sciences and biotechnology startups founded by Harvard faculty, alumni, students, and postdoctoral scholars. | $3.5M | Seed | Mar 13, 2019 |  |
| Terray Therapeutics | Terray Therapeutics is a biotechnology company that integrates experimentation and computation to enhance small molecule drug discovery. The platform generates extensive, precise data through a rapid design-make-test-analyze cycle, allowing for efficient exploration of chemical space. By focusing on both wet lab science and AI, the companyaddresses complex therapeutic challenges across various targets. | $5M | Seed | Mar 13, 2019 |  |
| SchoolCare | SchoolCare delivers free health technology for K-12 public schools to help school nurses deliver care and keep students safe. It is a digital health platform for the largest and most consistent health delivery system in the country. Their mission is to work with partners to provide a unified health record for every family. SchoolCare leveragespediatric health data and this country’s most successful public health organization, the K-12 school system, to improve outcomes and learn about clinical health data outside of the provider’s office. Traditional care coordination stops short of sending essential care instructions to School Nurses and thus increases the risk of stopped or inconsistent post-discharge care delivery. By closing the link in the pediatric care continuum, children stay healthy and get better faster. | $24.3M | Series C | Feb 15, 2019 |  |

10 of 20 investments shown.

## Co-investors
- [Innovation Endeavors](https://shizune.co/investors/profile/innovation-endeavors) — VC Fund, 4 deals together
- [KdT Ventures](https://shizune.co/investors/profile/kdt-ventures) — VC Fund, 4 deals together
- [Two Sigma Ventures](https://shizune.co/investors/profile/two-sigma-ventures) — VC Fund, 4 deals together
- [XTX Ventures](https://shizune.co/investors/profile/xtx-ventures) — VC Fund, 4 deals together
- [Scottish Widows Investment Partnership](https://shizune.co/investors/profile/scottish-widows-investment-partnership) — VC Fund, 3 deals together
- [7wire Ventures](https://shizune.co/investors/profile/7wire-ventures) — VC Fund, 2 deals together

## About Digitalis Ventures

VC Fund · New York, United States

Digitalis is a venture capital firm that that invests in solutions to complex problems in human and animal health. Digitalis partners with entrepreneurs, inventors, and scientists across all stages of venture investing, and our investments span the full continuum of the healthcare ecosystem. It was founded in 2016 and is Headquartered in New York,New York with regional offices in Boston, Los Angeles, and San Francisco.

5 contacts available at Digitalis Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Amit Bansal | Partner | https://shizune.co/investors/profile/amit-bansal-6 |
| Cindy Cole | Partner | https://shizune.co/investors/profile/cindy-cole |
| Dac Nguye | Technical Partner | https://shizune.co/investors/profile/dac-nguye |
| Drew Taylor | Partner | https://shizune.co/investors/profile/drew-taylor-2 |
| Geoffrey W. Smith | founder and managing partner | https://shizune.co/investors/profile/geoffrey-w-smith |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Geoffrey W. Smith invest in?

Geoffrey W. Smith invests primarily in Biotechnology, Therapeutics and Health Care startups, most often at Series B and Seed stage. Most of the 20 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Geoffrey W. Smith last invest?

The most recent investment recorded for Geoffrey W. Smith closed in Jun 2026. Shizune tracks 20 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co